The Siteman Cancer Center has been accepted into The National Comprehensive Cancer Network (NCCN), an alliance of the world’s leading cancer centers. The designation will allow Siteman Cancer Center access to and the ability to further improve cancer care guidelines.
With this addition, NCCN now comprises 20 centers dedicated to improving the quality, effectiveness and efficiency of oncology practice so patients can live better lives.
In addition to treatment excellence, the Siteman Cancer Center also provides access to clinical studies for all disease types and reaches out to more than 30,000 people yearly with cancer screening and education programs.
“We welcome the Siteman Cancer Center to the NCCN,” said William T. McGivney, Ph.D., chief executive officer of NCCN. “Siteman is recognized internationally as a leader in the development and delivery of high quality cancer care.
“Siteman will serve to geographically complement other NCCN members in our unique, premier network,” McGivney said.
Timothy J. Eberlein, M.D., the Bixby Professor of Surgery, professor of pathology and immunology, head of the Department of Surgery and director of Siteman, said, “As an NCCN member, the Siteman Cancer Center will be involved in the planning, development, and validation of therapies that represent the future of cancer care. Oncologists at Siteman Cancer Center — medical, radiation and surgical oncologists — will not only contribute to the development of new protocols based upon the extensive basic and clinical research in cancer carried out here, but will also bring other ideas back to Siteman Cancer Center, creating new avenues of investigation and innovative patient care.
“Patients at Siteman Cancer Center will benefit from access to the most advanced clinical treatment protocols, receiving care from oncologists engaged in emerging technology, in a system dedicated to continuous quality improvement,” Eberlein added.